The DOI matches its Crossref record; 30 of the 30 references it cites were found in a registry or an index.
Trial of Galcanezumab in Prevention of Episodic Cluster Headache
Open accessAbstract
BACKGROUND: Episodic cluster headache is a disabling neurologic disorder that is characterized by daily headache attacks that occur over periods of weeks or months. Galcanezumab, a humanized monoclonal antibody to calcitonin gene-related peptide, may be a preventive treatment for cluster headache. METHODS: We enrolled patients who had at least one attack every other day, at least four total attacks, and no more than eight attacks per day during a baseline assessment, as well as a history of cluster headache periods lasting at least 6 weeks, and randomly assigned them to receive galcanezumab (at a dose of 300 mg) or placebo, administered subcutaneously at baseline and at 1 month. The primary end point was the mean change from baseline in the weekly frequency of cluster headache attacks across weeks 1 through 3 after receipt of the first dose. The key secondary end point was the percentage of patients who had a reduction from baseline of at least 50% in the weekly frequency of cluster headache attacks at week 3. Safety was also assessed. RESULTS: Recruitment was halted before the trial reached the planned sample size of 162 because too few volunteers met the eligibility criteria. Of 106 enrolled patients, 49 were randomly assigned to receive galcanezumab and 57 to receive placebo. The mean (±SD) number of cluster headache attacks per week in the baseline period was 17.8±10.1 in the galcanezumab group and 17.3±10.1 in the placebo group. The mean reduction in the weekly frequency of cluster headache attacks across weeks 1 through 3 was 8.7 attacks in the galcanezumab group, as compared with 5.2 in the placebo group (difference, 3.5 attacks per week; 95% confidence interval, 0.2 to 6.7; P = 0.04). The percentage of patients who had a reduction of at least 50% in headache frequency at week 3 was 71% in the galcanezumab group and 53% in the placebo group. There were no substantial between-group differences in the incidence of adverse events, except that 8% of the patients in the galcanezumab group had injection-site pain. CONCLUSIONS: Galcanezumab administered subcutaneously at a dose of 300 mg once monthly reduced the weekly frequency of attacks of episodic cluster headache across weeks 1 through 3 after the initial injection, as compared with placebo. (Funded by Eli Lilly; ClinicalTrials.gov number, NCT02397473.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The International Classification of Headache Disorders, 3rd edition (beta version)
Headache Classification Committee of the International Headache Society (IHS) (2013) · Cephalalgia · doi:10.1177/0333102413485658 · Cited by 8,229
Posner, K., Brown, G. K., Stanley, B., Brent, D. A., Yershova, K. V., Oquendo, M. A., Currier, G. W., Melvin, G. A., Greenhill, L., Shen, S., et al. (2011) · American Journal of Psychiatry · doi:10.1176/appi.ajp.2011.10111704 · Cited by 5,157
Small sample inference for fixed effects from restricted maximum likelihood
Kenward, M. G., & Roger, J. H. (1997) · Biometrics · doi:10.2307/2533558 · Cited by 4,552
Abraham, J. (2010) · Handbook of Transnational Economic Governance Regimes · doi:10.1163/ej.9789004163300.i-1081.897 · Cited by 2,582
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Vasoactive peptide release in the extracerebral circulation of humans during migraine headache
Goadsby, P. J., Edvinsson, L., & Ekman, R. (1990) · Annals of Neurology · doi:10.1002/ana.410280213 · Cited by 1,597
Self-citationHypothalamic activation in cluster headache attacks
May, A., Bahra, A., Büchel, C., Frackowiak, R. S., & Goadsby, P. J. (1998) · The Lancet · doi:10.1016/s0140-6736(98)02470-2 · Cited by 1,123
Self-citationCGRP as the target of new migraine therapies — successful translation from bench to clinic
Edvinsson, L., Haanes, K. A., Warfvinge, K., & Krause, D. N. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0003-1 · Cited by 999
Goadsby, P. J., & Edvinsson, L. (1994) · Brain · doi:10.1093/brain/117.3.427 · Cited by 681
Self-citationTreatment of Acute Cluster Headache with Sumatriptan
The Sumatriptan Cluster Headache Study Group* (1991) · New England Journal of Medicine · doi:10.1056/nejm199108013250505 · Cited by 429
Pathophysiology of cluster headache: a trigeminal autonomic cephalgia
Goadsby, P. J. (2002) · The Lancet Neurology · doi:10.1016/s1474-4422(02)00104-7 · Cited by 426
Self-citationLeone, M., Franzini, A., & Bussone, G. (2001) · New England Journal of Medicine · doi:10.1056/nejm200111083451915 · Cited by 401
Self-citationProtein size and cerebrospinal fluid composition
Felgenhauer, K. (1974) · Klinische Wochenschrift · doi:10.1007/bf01466734 · Cited by 396
Dodick, D. W., Goadsby, P. J., Spierings, E. L. H., Scherer, J. C., Sweeney, S. P., & Grayzel, D. S. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(14)70128-0 · Cited by 368
Self-citationDiagnosis, pathophysiology, and management of cluster headache
Hoffmann, J., & May, A. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30405-2 · Cited by 289
Fanciullacci, M., Alessandri, M., Figini, M., Geppetti, P., & Michelacci, S. (1995) · Pain · doi:10.1016/0304-3959(94)00097-x · Cited by 279
Verapamil in the prophylaxis of episodic cluster headache: A double-blind study versus placebo
Leone, M., D’Amico, D., Frediani, F., Moschiano, F., Grazzi, L., Attanasio, A., & Bussone, G. (2000) · Neurology · doi:10.1212/wnl.54.6.1382 · Cited by 234
Self-citationSkljarevski, V., Oakes, T. M., Zhang, Q., Ferguson, M. B., Martinez, J., Camporeale, A., Johnson, K. W., Shan, Q., Carter, J., Schacht, A., et al. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2017.3859 · Cited by 172
Self-citationEffectiveness of Intranasal Zolmitriptan in Acute Cluster Headache
Cittadini, E., May, A., Straube, A., Evers, S., Bussone, G., & Goadsby, P. J. (2006) · Archives of Neurology · doi:10.1001/archneur.63.11.nct60002 · Cited by 153
Self-citationEffect of Infusion of Calcitonin Gene-Related Peptide on Cluster Headache Attacks
Vollesen, A. L. H., Snoer, A. H., Beske, R. P., Guo, S., Hoffmann, J., Jensen, R., & Ashina, M. (2018) · JAMA Neurology · doi:10.1001/jamaneurol.2018.1675 · Cited by 147
Lessons From 8 Years' Experience of Hypothalamic Stimulation in Cluster Headache
Leone, M., Cecchini, A., Franzini, A., Broggi, G., Cortelli, P., Montagna, P., May, A., Juergens, T., Cordella, R., Carella, F., et al. (2008) · Cephalalgia · doi:10.1111/j.1468-2982.2008.01627.x · Cited by 140
Self-citationElectrocardiographic abnormalities in patients with cluster headache on verapamil therapy
Cohen, A. S., Matharu, M. S., & Goadsby, P. J. (2007) · Neurology · doi:10.1212/01.wnl.0000267319.18123.d3 · Cited by 133
Self-citationNesbitt, A. D., & Goadsby, P. J. (2012) · BMJ · doi:10.1136/bmj.e2407 · Cited by 130
Self-citationImpairment in episodic and chronic cluster headache
Jürgens, T. P., Gaul, C., Lindwurm, A., Dresler, T., Paelecke–Habermann, Y., Schmidt‐Wilcke, T., Lürding, R., Henkel, K., & Leinisch, E. (2010) · Cephalalgia · doi:10.1177/0333102410391489 · Cited by 118
Lipton, R. B., Micieli, G., Russell, D., Solomon, S., Tfelt‐Hansen, P. C., & Waldenlind, E. (1995) · Cephalalgia · doi:10.1046/j.1468-2982.1995.1506452.x · Cited by 80
Lipton, R. B., Micieli, G., Russell, D., Solomon, S., Tfelt‐Hansen, P. C., & Waldenlind, E. (1995) · Cephalalgia · doi:10.1046/j.1468-29821995.1506452.x · Cited by 77
Suicide in primary headaches in 48 countries: A physician-survey based study
Trejo-Gabriel-Galan, J. M., Aícua‐Rapún, I., Cubo, E., & Velasco-Bernal, C. (2017) · Cephalalgia · doi:10.1177/0333102417714477 · Cited by 29
NParCov3: ASAS/IMLMacro for Nonparametric Randomization-Based Analysis of Covariance
Zink, R. C., & Koch, G. G. (2012) · Journal of Statistical Software · doi:10.18637/jss.v050.i03 · Cited by 17
Senn (1998) · doi:10.1002/(sici)1097-0258(19980815/30)17:15/16
Cited by
CGRP physiology, pharmacology, and therapeutic targets: migraine and beyond
Russo, A. F., & Hay, D. L. (2023) · Physiological Reviews · doi:10.1152/physrev.00059.2021 · Cited by 382
Metadata
- Authors
- Goadsby, P. J., Dodick, D. W., Leone, M., Bardos, J. N., Oakes, T. M., Millen, B. A., Zhou, C., Dowsett, S. A., Aurora, S. K., Ahn, A. H., Yang, J.-Y., Conley, R. R., & Martinez, J. M.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2019-07-11
- Volume
- 381
- Issue
- 2
- Pages
- 132-141
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2961330592
- Cited by
- 265
- References
- 30
- FWCI
- 25.48
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.